Compare CIM & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIM | OPK |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2007 | 1995 |
| Metric | CIM | OPK |
|---|---|---|
| Price | $12.41 | $1.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $15.25 | $2.28 |
| AVG Volume (30 Days) | 847.5K | ★ 4.1M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 11.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $191,573,000.00 | ★ $642,067,000.00 |
| Revenue This Year | $11.44 | N/A |
| Revenue Next Year | $21.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.85 | $1.11 |
| 52 Week High | $15.37 | $2.04 |
| Indicator | CIM | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 57.15 |
| Support Level | $12.27 | $1.24 |
| Resistance Level | $12.81 | $1.33 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 18.16 | 92.31 |
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.